Publications by authors named "Eztizen Labrador"
Background: A substantial proportion of patients with giant cell arteritis (GCA) relapse despite standard therapy with glucocorticoids, methotrexate and tocilizumab. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway is involved in the pathogenesis of GCA and JAK inhibitors (JAKi) could be a therapeutic alternative. We evaluated the effectiveness of JAKi in relapsing GCA patients in a real-world setting and reviewed available literature.
View Article and Find Full Text PDFArticle Synopsis
- - The study assessed safety events in patients with Autoinflammatory diseases using data from the Eurofever registry, focusing on adverse events (AEs) reported since 2009.
- - A total of 2464 patients were included in the analysis, highlighting that 479 AEs were reported, with serious AEs and drug-related AEs being particularly noted, especially in relation to biologic DMARDs and colchicine.
- - The findings underscore the need for consistent monitoring of AEs in rare conditions to better understand the safety of treatments.
Article Synopsis
- VEXAS syndrome is an adult-onset autoinflammatory disease caused by postzygotic genetic variants, affecting males with symptoms like skin lesions, fever, and arthritis at a mean age of 67.5 years.
- In a study of 42 patients, 30 were identified with pathogenic genetic variants and showed varying degrees of glucocorticoid dependence for symptom management.
- The research revealed that these variants were present in both blood and non-blood tissues, challenging the previous understanding that these genetic changes were limited to myeloid (blood) cells.